RxDoctor Payments Data

Catherine Mathes, MD

Internal Medicine · Knoxville, TNNPI 1427092808

Payments from drug & device makers

$6,723in general payments, 2019–2025

Across 467 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novo Nordisk$647
  • AbbVie$583
  • Merck$536
  • Lilly USA, LLC$511
  • GSK$425
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,717100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,723 in reported general payments places this provider in the 85th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$196,763
Medicare patients
350
Services billed
5,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban144$136,930
OzempicSemaglutide80$83,766
XareltoRivaroxaban52$61,861
JardianceEmpagliflozin38$48,671
JanuviaSitagliptin Phosphate44$40,953
ProliaDenosumab24$40,827
ViberziEluxadoline12$16,533
ShingrixVaricella-Zoster Ge/As01b/Pf66$14,953
Breo ElliptaFluticasone/Vilanterol18$14,022
GemtesaVibegron11$8,874
Spiriva RespimatTiotropium Bromide11$8,554
ArexvyRsvpref3 Antigen/As01e/Pf25$7,935
BrilintaTicagrelor12$5,614
Levothyroxine Sodium510$4,159
DayvigoLemborexant12$3,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,046$136,930144 claims
Novo NordiskOzempic$647$83,76680 claims
Johnson & JohnsonXarelto$116$61,86152 claims
Boehringer IngelheimJardiance, Spiriva Respimat$229$57,22549 claims
MerckJanuvia$536$40,95344 claims
AmgenProlia$225$40,82724 claims
GSKShingrix, Breo Ellipta, Arexvy$425$36,910109 claims
AbbVieViberzi, Synthroid$583$20,09396 claims
Sumitomo Pharma America, Inc.Gemtesa$90$8,87411 claims
AstraZenecaBrilinta$374$5,61412 claims
Eisai Inc.Dayvigo$57$3,79212 claims
Sanofi-aventis U.S. LLCLantus$44$3,11114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →